CJC-1295 with DAC

Mechanism

A long-acting version of CJC-1295 that stays active in your body for about a week thanks to a special attachment called DAC (Drug Affinity Complex) that binds to albumin in your blood. You inject it once or twice a week instead of daily. It raises baseline GH levels steadily rather than creating sharp pulses.

Effects

ENDOCRINE / GH AXIS [Tier 1 – Human Clinical]: CJC-1295 DAC (Drug Affinity Complex) is a long-acting growth hormone releasing hormone (GHRH) analog with a half-life of 6-8 DAYS due to its DAC modification that enables covalent binding to serum albumin. This creates a sustained, continuous GHRH signal rather than pulsatile stimulation. Produces a sustained elevation of GH levels (2-10x baseline) and IGF-1 (1.5-3x baseline) that persists for 7-14 days after a single injection. Multiple Phase I/II studies confirm robust, dose-dependent GH and IGF-1 elevation. METABOLIC [Tier 2 – Limited Human]: Continuous GH elevation improves lipolysis and body composition over weeks of use. IGF-1 elevation supports anabolic processes. However, the non-pulsatile nature of GH release is a point of controversy (see practitioner guide). May affect glucose metabolism through sustained GH elevation — insulin sensitivity monitoring recommended. MUSCULOSKELETAL [Tier 2 – Limited Human]: Through sustained GH/IGF-1 elevation, supports muscle protein synthesis, connective tissue repair, and recovery. Effects build over weeks (not immediate like a GHRP pulse). Collagen synthesis enhancement for joint/tendon health. Bone density support with long-term use. SLEEP / RECOVERY [Tier 2 – Practitioner Reported]: Deep sleep enhancement commonly reported. Recovery from training notably improved. Skin quality improvements (GH-mediated collagen synthesis). These effects are consistent with the known effects of sustained GH elevation. BODY COMPOSITION [Tier 2 – Limited Human]: Favorable shifts in body composition — reduced visceral fat, maintained or increased lean mass. Effects are gradual (4-8 weeks for noticeable changes) but sustained.

Practitioner Guide

CLINICAL POSITIONING: CJC-1295 DAC is the "set and forget" GH peptide — once or twice weekly injections producing continuous GH/IGF-1 elevation. This convenience is its greatest strength and, depending on your clinical philosophy, potentially its greatest weakness. THE DAC vs NO-DAC DEBATE — THE MOST CONTENTIOUS TOPIC IN GH PEPTIDES: CJC-1295 DAC (this peptide): • Half-life: 6-8 days. Inject 1-2x per week. • Creates CONTINUOUS GH elevation — GH levels stay elevated 24/7 for days. • Pro: Convenient (1-2 injections/week). Consistent IGF-1 elevation. Simple protocol. Excellent compliance. • Con: Non-physiological. Natural GH is released in PULSES (6-12 per day). Continuous elevation may cause more side effects (water retention, insulin resistance, joint pain) and could theoretically downregulate GH receptors over time. Mod GRF 1-29 / CJC-1295 NO DAC: • Half-life: ~30 minutes. Inject 2-3x daily. • Creates PULSATILE GH release — mimics natural GH secretion patterns. • Pro: More physiological. Less water retention. May preserve GH receptor sensitivity better. Less insulin impact per pulse. • Con: Requires 2-3 daily injections. Less convenient. More variable IGF-1 elevation. PRACTITIONER CONSENSUS (as of 2026): • Most experienced peptide practitioners prefer Mod GRF 1-29 (no DAC) + a GHRP for optimization — it is more physiological. • CJC-1295 DAC is preferred for patients who will not comply with multiple daily injections, or for those who want simplicity. • Some practitioners use CJC-1295 DAC as a "base" (1x/week) with Ipamorelin pulses (2-3x/day) on top for a hybrid approach. • The theoretical concerns about continuous GH elevation have NOT been validated in human studies — this debate remains opinion-driven, not evidence-driven. DOSING PROTOCOLS: • Standard: 2 mg subcutaneous once weekly (typically Sunday evening). This produces sustained IGF-1 elevation throughout the week. • Conservative: 1 mg once weekly. Good for patients new to GH peptides or those sensitive to GH effects. • Aggressive: 2 mg twice weekly (e.g., Sunday + Wednesday). Higher IGF-1 levels but more side effects. • Hybrid: 2 mg CJC-1295 DAC once weekly + Ipamorelin 100-200 mcg 1-2x daily for additional pulsatile stimulation. TIMING: • Evening/pre-bed injection preferred (synergizes with nocturnal GH release). • Can be injected any time — the long half-life means timing is less critical than with GHRPs. • Empty stomach not strictly necessary (GHRH analog, not ghrelin mimetic), but fasting may optimize absorption. BLOOD WORK — CRITICAL FOR DAC USERS: • Baseline: IGF-1, fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel. • 4-week: IGF-1 (should be elevated — target 250-350 ng/dL for optimization, depending on age). Fasting glucose and insulin (watch for early insulin resistance). • 8-week: Full panel. If fasting insulin rising >15 mIU/L or HOMA-IR >2.5, consider reducing dose or switching to no-DAC. • 12-week: Full panel plus reassessment. • IGF-1 MUST be monitored. With DAC, it is easy to push IGF-1 supraphysiological (>400 ng/dL), which carries theoretical cancer risk (see research summary). MANAGING SIDE EFFECTS: • Water retention/bloating: Very common in first 2-4 weeks with DAC. More pronounced than with pulsatile protocols. Manage with adequate water intake, moderate sodium, natural diuretics (dandelion root). Usually self-resolving by week 4-6. • Joint pain/carpal tunnel symptoms: GH-mediated. Reduce dose. More common with DAC than pulsatile due to sustained elevation. • Insulin resistance: Monitor closely. If fasting glucose rising or insulin climbing, add berberine (500 mg 2-3x daily with meals) or discuss metformin with physician. Consider switching to no-DAC protocol. • Head pressure/headaches: Occasionally reported in first week. Usually transient. CYCLE: 12-16 weeks on, 4-8 weeks off. Some practitioners run 6 months continuously with blood work monitoring. The long half-life means effects persist for 2-3 weeks after last injection.

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  CJC-1295 DAC produces sustained GH/IGF-1 elevation lasting 8-14 days due to albumin binding. Prolonged IGF-1 elevation is mitogenic and may accelerate tumor growth. The sustained release profile makes this particularly dangerous compared to shorter-acting GH peptides.
  Action: Do not use in patients with any active cancer. Cancer survivors should obtain oncologist clearance. Consider shorter-acting alternatives (CJC-1295 No DAC) for better control.
• hard stop — Pregnancy
  No human safety data during pregnancy. Sustained supraphysiologic GH/IGF-1 elevation poses risk to fetal development. Long half-life means effects persist for days after last dose.
  Action: Do not use during pregnancy. Discontinue well before planned conception due to long duration of action.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Sustained GH/IGF-1 elevation may affect nursing infant. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use.
  Action: Do not provide to individuals under 18.
• requires physician — Diabetes
  Sustained GH elevation over 8-14 days persistently antagonizes insulin action and increases hepatic glucose output. More difficult to manage than pulsatile GH secretagogues due to continuous exposure.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Consider shorter-acting alternatives for better glycemic management.

Evidence

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

  Teichman SL, Neale A, Lawrence B, Gagnon C, Caber JP, Bhatt RS (2006) — Journal of Clinical Endocrinology and Metabolism — PMID: 16352683

  Single subcutaneous injections of CJC-1295 (DAC-conjugated GHRH analog) produced dose-dependent increases in GH and IGF-1 lasting 6-8 days in healthy adults. Mean IGF-1 levels increased 1.5-3 fold above baseline with sustained elevations for up to 2 weeks. Well-tolerated with injection site reactions as primary adverse event.

  moderate

Research Summary

TIER 1 (Human Clinical Trials): • Teichman et al. (2006, JCEM): Phase I/II study. Single doses of CJC-1295 DAC (30-60-125 mcg/kg) produced dose-dependent GH elevation lasting 6+ days and IGF-1 elevation lasting 9-11 days. 2-10x baseline GH, 1.5-3x baseline IGF-1. • Multiple ascending dose study: Weekly injections produced sustained IGF-1 elevation with continued dosing. No tachyphylaxis (GH response maintained over multiple doses — contrast with GHRP desensitization). • Safety: Generally well-tolerated. Injection site reactions (erythema, induration) were the most common adverse events. TIER 2 (Limited Human / Strong Preclinical): • Pharmacokinetic characterization of DAC (Drug Affinity Complex) technology: covalent albumin binding extends half-life from minutes to days. • IGF-1 dose-response curves establishing therapeutic dosing ranges. • Comparison studies suggesting DAC version produces more sustained but less physiological GH elevation than pulsatile GHRH administration. TIER 3 (Preclinical / Mechanistic): • GHRH receptor binding studies: CJC-1295 retains full GHRH-R agonist activity despite modifications. • Animal studies confirming prolonged pharmacokinetic profile and sustained GH axis stimulation. • Theoretical modeling of continuous vs pulsatile GH stimulation on receptor sensitivity (supports concern about receptor downregulation but not validated in humans). EVIDENCE GAPS: No Phase III trials. No long-term (>6 month) human safety data. The DAC vs no-DAC debate lacks head-to-head clinical trial data. Cancer risk with sustained IGF-1 elevation (theoretical, based on epidemiological IGF-1/cancer correlation data) not specifically studied. Optimal dosing interval (weekly vs biweekly) not established by controlled trials.